Amgen
Search results
Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead is committed to helping improve the lives of people around the world by bringing forward medicines that prevent, treat and cure devastating diseases. We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development, as well as collaborations with academic and ...
Apr 8, 2024 · May 07, 2024. Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024. April 30, 2024. Gilead Sciences to Present at Upcoming Investor Conferences. April 26, 2024. FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV. April 25, 2024. Gilead Sciences Announces First Quarter 2024 Financial Results
Apr 25, 2024 · Learn about the investigational medicines in Gilead's pipeline with the potential to help advance care in COVID-19, HIV, viral hepatitis, cancer and inflammation.
As a pioneer and leader in antiviral drug development, Gilead developed the first approved antiviral medicine for the treatment of COVID-19. Building on more than three decades of resources and research, we were able to quickly demonstrate its effectiveness and ramp up production to help reduce the burden of the pandemic.
Early Career Opportunities | Gilead. Our Investment in Early Talent. Our people make it possible. Their dedication and focus have led to a legacy of breakthroughs once thought impossible, and their drive helps us continue to create a better, healthier world for all people.
Jul 22, 2023 · Rich Pedroncelli/Associated Press. Today, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for H.I.V. treatment and prevention,...
